Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-003999-39 | EudraCT Number |
Not provided
Not provided
Not provided
The study was withdrawn following a strategic portfolio re-prioritization.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate efficacy and safety of PF-06826647 in moderate to severe ulcerative colitis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Placebo |
|
| PF-06826647 100 mg once a day (QD) | Experimental | PF-06826647 100 mg once a day (QD) |
|
| PF-06826647 300 mg QD | Experimental | PF-06826647 300 mg QD |
|
| PF-06826647 600 mg QD | Experimental | PF-06826647 600 mg QD |
|
| Open Label Extension, PF-06826647 400 mg QD | Experimental | PF-06826647 400 mg QD |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-06826647 100 mg QD | Drug | Investigational Product |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants achieving endoscopic response | Endoscopic response is defined by Mayo endoscopic index < 2 | At Week 8 |
| Number of Adverse Events (AEs), Serious Adverse Events (SAEs) based on severity and withdrawals due to adverse events (AEs) | At Week 60 | |
| Number of Participants With Clinical Laboratory Abnormalities | Following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).](streamdown:incomplete-link) | At Week 60 |
| Percentage of participants with clinically significant changes in Electrocardiogram (ECG) | Clinical significant changes in ECG | At Week 60 |
| Number of Participants With Categorical changes from baseline in Vital Signs Data | Number of participants with increase from baseline in sitting SBP and DBP of greater than or equal to 30 mmHg at Week 60. | At Week 60 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants achieving clinical remission | Clinical remission is defined by total Mayo score of ≤ 2 with no individual subscore of > 1 | At Week 8 and 60 |
| Percentage of participants achieving endoscopic remission |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hope Clinical Research | Canoga Park | California | 91303 | United States | ||
| ADVA Clinical Research |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PF-06826647 300 mg QD |
| Drug |
Investigational Product |
|
| PF-06826647 600 mg QD | Drug | Investigational Product |
|
| Placebo | Drug | Matched Placebo |
|
| PF-6826647 400 mg QD | Drug | Investigational Product |
|
Endoscopic remission is defined as Mayo endoscopic index of 0
| At Week 8 and 60 |
| Percentage of participants achieving mucosal healing | Mucosal healing is defined as both total Mayo score and histologic index of ≤ 1. | At Week 8 and 60 |
| Percentage of participants achieving clinical response | Clinical response is defined as a decrease from baseline of at least 3 points in total Mayo score with at least 30% change, accompanied by at least one point decrease or absolute score of 0 or 1 in rectal bleeding subscore. | At Week 8 and 60 |
| Mean change from baseline in partial Mayo score over time | Up to 60 weeks |
| Change from baseline in total Mayo score | At Week 8 and 60 |
| Number of Adverse Events (AEs), Serious Adverse Events (SAEs) based on severity and withdrawals due to adverse events (AEs) | At Week 8 |
| Number of Participants With Clinical Laboratory Abnormalities | Following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).](streamdown:incomplete-link) | At Week 8 |
| Percentage of participants with clinically significant changes in Electrocardiogram (ECG) | Clinically significant changes from baseline in ECG (heart rate, QT, QTc, PR and QRS intervals) | At Week 8 |
| Number of Participants With Categorical Vital Signs Data | Number of participants with increase from baseline in sitting SBP and DBP of greater than or equal to 30 mmHg at Week 8. | At Week 8 |
| Inglewood |
| California |
| 90301 |
| United States |
| Centinela Valley Endoscopy Center | Inglewood | California | 90301 | United States |
| Inglewood Imaging Center | Inglewood | California | 90301 | United States |
| Surinder Saini, M.D., Inc. | Newport Beach | California | 92660 | United States |
| Renaissance Imaging Center (CT/Xray) | Northridge | California | 91325 | United States |
| Valley Endoscopy Center (Colonoscopy/Flexible sigmoidoscopy) | Tarzana | California | 91356 | United States |
| Saludmax Medical Corp. | Miami | Florida | 33165 | United States |
| Alliance Clinical Research of Tampa | Tampa | Florida | 33615 | United States |
| Gastroenterology Consultants P.C. | Roswell | Georgia | 30076 | United States |
| Internal Medicine Associates (c/o TrialSpark, Inc.) | Merrillville | Indiana | 46410 | United States |
| Gastroenterology Associates of New Jersey, LLC (c/o TrialSpark, Inc.) | Clifton | New Jersey | 07013 | United States |
| Physicians Ambulatory Surgery Center, LLC, dba Physicians Endoscopy Center | Houston | Texas | 77063 | United States |
| Houston Digestive Diseases Consultants, P.A. | Houston | Texas | 77074 | United States |
| Memorial Hermann SW Surgery Center | Houston | Texas | 77074 | United States |
| Gastroenterology Consultants of San Antonio | San Antonio | Texas | 78230 | United States |
| Victorium Clinical Research | San Antonio | Texas | 78230 | United States |
| South Texas Radiology Imaging Center | San Antonio | Texas | 78258 | United States |
| Sugar Lakes Family Practice, PA | Sugar Land | Texas | 77479 | United States |
| Gastroenterolgy Associates of Northern Virginia | Fairfax | Virginia | 22031 | United States |
| Gastroenterology Associates of Northern Virginia | Fairfax | Virginia | 22031 | United States |
| Verity Research, Inc. | Fairfax | Virginia | 22031 | United States |
| Fair Oaks Imaging Center- Reston Radiology Consultants | Fairfax | Virginia | 22033 | United States |
| Associates in Gastroenterology (c/o TrialSpark, inc) | Woodbridge | Virginia | 22192 | United States |
| ID | Term |
|---|---|
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D003092 | Colitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D015212 | Inflammatory Bowel Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000720458 | ropsacitinib |
Not provided
Not provided
Not provided